Current management for the disease often copyright on subcutaneous administrations of GLP-1 medications, a procedure that can be challenging for people. Researchers are vigorously creating innovative administration methods to optimize individual acceptance and outcomes. These feature ingested formulations, through the nose delivery, and even implan